Buckle Up: DOJ Initiates Rulemaking to Reschedule Marijuana
FDA Law
MAY 21, 2024
and its abuse may lead to only moderate or low physical dependence or high psychological dependence. DEA noted that “there is considerable variability in the cannabinoid concentrations and chemical constituency among marijuana samples and that the interpretation of clinical data related to marijuana is complicated.” 21 U.S.C. §
69 
Let's personalize your content